A generic drug manufacturer may employ the counterclaim provision of the Hatch-Waxman Act to force correction of a use code that inaccurately describes the brand’s patent as covering a particular method of using a drug. U.S. Supreme Court. Caraco Pharmaceutical Laboratories, Ltd. v. Novo Nordisk A/S, No. 10-844. April 17, 2012. Lawyers USA No. 993-3730.
Scroll To Top